Taking responsibility: Asilomar and its legacy
By J. Benjamin Hurlbut,
Science
| 01. 30. 2025
In February 1975, leading molecular biologists gathered at the Asilomar conference center on the California coast to evaluate risks of the emerging technology of recombinant DNA and to establish guidelines to govern research. The meeting is remembered as a defining moment in the making of molecular biology. Yet its legacy lies not in specific rules it developed but in the approach to scientific self-regulation that it crystallized. Five decades later, this near-mythic “meeting that changed the world” is held up as a precedent to celebrate and a model to emulate: Scientists take responsibility for governing themselves, solidifying public trust while securing future benefits of technology for society. But although this may elicit public acquiescence and secure scientific autonomy in the short run, ultimately it has engendered reactive distrust. The 50th anniversary affords a moment for taking stock of Asilomar’s legacy and its implications for science and democracy. Its lessons are difficult.
The Asilomar meeting is held up as an exemplar of how scientists can navigate between the Scylla of technological risk and the Charybdis of public reaction and overregulation (...
Related Articles
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Paul Knoepfler, Stat | 06.24.2026
What if you could precisely change the genome of a pre-implantation human embryo and then safely use that embryo to try to generate a healthier person? It’s a wild idea, but one that technology over the past decade has steadily...